Written by: Ricky Bell
Having spent a decade advising clinical laboratories and health systems on revenue cycle management, I can tell you that molecular diagnostics remains one of the most volatile operational areas in healthcare. Federal spending on genetic testing under Medicare Part B now sits above $3.6 billion every year. That rapid ...